Ingo V. Hartung

Ingo V. Hartung

Auto-generated profile, based on publicly available information

Ingo V. Hartung

Merck Healthcare KGaA, Darmstadt, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
IHIngo V. Hartung
Ingo V. Hartung
JRJoachim Rudolph
Joachim Rudolph
MMMary M. Mader
Mary M. Mader
MMMonique Mulder
Monique Mulder
PWPaul Workman
Paul Workman
Within druggable target space, new small-molecule modalities, particularly covalent inhibitors and targeted degraders, have expanded the repertoire of medicinal chemists. Molecules with such modes of action have a large potential not only as drugs but also as chemical probes. Criteria have previously been established to describe the potency, selectivity, and properties of small-molecule probes that are qualified to enable the interrogation and validation of drug targets. These definitions have been tailored to reversibly acting modulators but fall short in their applicability to other modalities. While initial guidelines have been proposed, we delineate here a full set of criteria for the characterization of covalent, irreversible inhibitors as well as heterobifunctional degraders ("proteolysis-targeting chimeras", or PROTACs) and molecular glue degraders. We propose modified potency and selectivity criteria compared to those for reversible inhibitors. We discuss their relevance and highlight examples of suitable probe and pathfinder compounds.

3 December 2021 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
SMSusanne Müller
Susanne Müller
SASuzanne Ackloo
Suzanne Ackloo
ACArij Al Chawaf
Arij Al Chawaf
BABissan Al-Lazikani
Bissan Al-Lazikani
AAAlbert Antolin
Albert Antolin
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
Twenty years after the publication of the first draft of the human genome, our knowledge of the human proteome is still fragmented. Target 2035 aims to develop a pharmacological modulator for every protein in the human proteome to fill this gap.

1 January 2023 in Nature Reviews Chemistry
Verified
Journal Article
Closed access
PDF file
IHIngo V. Hartung
Ingo V. Hartung
BHBayard R. Huck
Bayard R. Huck
ACAlejandro Crespo
Alejandro Crespo

28 February 2023 in ChemMedChem
Verified
Journal Article
Closed access
JKJohannes Krieger
Johannes Krieger
FSFiona J. Sorrell
Fiona J. Sorrell
AWAnsgar A. Wegener
Ansgar A. Wegener
BLBirgitta Leuthner
Birgitta Leuthner
FMFouzia Machrouhi‐Porcher
Fouzia Machrouhi‐Porcher
SSSarah Schlesiger
Sarah Schlesiger

2 December 2021 in Nature Catalysis
Verified
Journal Article
Closed access
PDF file
MAMickaël Avanthay
Mickaël Avanthay
RBRobin B. Bedford
Robin B. Bedford
CBCallum S. Begg
Callum S. Begg
DBDietrich Böse
Dietrich Böse
JCJonathan D. Clayden
Jonathan D. Clayden
HWHarry J. Wilkinson
Harry J. Wilkinson

11 April 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AVAlexandros Vakalopoulos
Alexandros Vakalopoulos
FWFrank Wunder
Frank Wunder
IHIngo V. Hartung
Ingo V. Hartung
GRGorden Redlich
Gorden Redlich
RJRolf Jautelat
Rolf Jautelat
MFMarkus Follmann
Markus Follmann